Gelteq’s gel technology enters US market through Healthy Extracts

MELBOURNE - Gelteq Limited (NASDAQ:GELS), a micro-cap company with a market capitalization of $14.5 million, announced Friday that its proprietary gel technology has entered the U.S. nutraceutical market through product launches by Healthy Extracts, Inc. (OTCQB:HYEX). According to InvestingPro data, the company currently trades at a high revenue multiple, reflecting market expectations for its growth potential.

The company reported these products are the first to reach Gelteq’s U.S. warehousing facility using its delivery platform, marking what the firm describes as a transition from research and development to active commercialization in the United States.

"We are pleased to see Gelteq’s technology expand into the U.S. market through our collaboration with Healthy Extracts," said Nathan Givoni, CEO of Gelteq.

The partnership with Healthy Extracts was first announced earlier this year, beginning with warehousing and fulfillment arrangements. The collaboration has now progressed to active sales and distribution, according to the press release.

Gelteq, headquartered in Melbourne, Australia, develops gel-based oral delivery solutions for various applications including prescription drugs, nutraceuticals, pet care, and sports nutrition. The company’s technology aims to address challenges in conventional drug delivery such as taste masking, swallowing difficulties, and precision dosing.

The announcement comes as Gelteq seeks to establish its presence in the U.S. market and potentially develop additional partnerships. The company completed its initial public offering on the Nasdaq earlier this year.

This information is based on a press release statement issued by Gelteq Limited.

In other recent news, Gelteq Limited has announced plans to initiate a preclinical bioequivalence study for its gel-based antihistamine formulation. The study, which will be conducted by Adgyl Lifesciences, aims to evaluate the potential of Gelteq’s proprietary gel technology to deliver an established antihistamine in a new format. Success in these preclinical trials could lead to human clinical trials and eventually U.S. FDA approval through the 505(b)(2) regulatory pathway. Additionally, Gelteq has entered into a memorandum of understanding with IDT Australia to establish a dedicated manufacturing facility. This partnership is intended to facilitate the scale-up and commercialization of Gelteq’s gel-based oral delivery platform. The new facility will support operations across pharmaceutical, nutraceutical, and animal health markets worldwide. These developments mark significant steps for Gelteq in advancing its technology and market reach.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.